Measuring reliability and validity of a newly developed stress instrument: Newly Diagnosed Breast Cancer Stress Scale

2013 ◽  
Vol 22 (17-18) ◽  
pp. 2417-2425 ◽  
Author(s):  
Tso-Ying Lee ◽  
Hsing-Hsia Chen ◽  
Mei-Ling Yeh ◽  
Hui-Ling Li ◽  
Kuei-Ru Chou
Keyword(s):  
Breast Cancer ◽  
Reliability And Validity ◽  
Newly Diagnosed ◽  
Stress Scale ◽  
Cancer Stress

Newly Diagnosed Breast Cancer Stress Scale

2013 ◽  
Author(s):  
Tso‐Ying Lee ◽  
Hsing‐Hsia Chen ◽  
Mei‐Ling Yeh ◽  
Hui‐Ling Li ◽  
Kuei‐Ru Chou
Keyword(s):  
Breast Cancer ◽  
Newly Diagnosed ◽  
Stress Scale ◽  
Cancer Stress

scholarly journals An Improved Stress-Scale Specifically Designed to Measure Stress of Women with Newly Diagnosed Breast Cancer

2021 ◽  
Vol 18 (5) ◽  
pp. 2346
Author(s):  
Tso-Ying Lee ◽  
Shih-Chun Hsing ◽  
Chin-Ching Li
Keyword(s):  
Breast Cancer ◽  
Factor Analysis ◽  
Root Mean Square ◽  
Goodness Of Fit ◽  
Medical Intervention ◽  
Mean Square ◽  
Newly Diagnosed ◽  
Breast Cancer Patients ◽  
Stress Scale ◽  
Fit Index

Most breast cancer patients are middle-aged women actively involved in establishing a family, developing a career, or raising children. With the exception of the Newly Diagnosed Breast Cancer Stress Scale (NDBCSS), few stress scales have been designed for women with breast cancer. This study checked the dimensionality of the NDBCSS by confirmatory factor analysis (CFA) and the results showed a poor fit, indicating an urgent need for improvement. Exploratory factor analysis (EFA) using the varimax rotation method was performed to improve the model, the revised NDBCSS (NDBCSS-R), which showed a good Kaiser-Meyer-Olkin value, Bartlett’s test of sphericity, and internal consistency reliability. The NDBCSS-R showed improved indices compared with NDBCSS, including: chi-square fit statistics/degree of freedom (CMIN/DF), goodness-of-fit index (GFI), adjusted goodness of fit index (AGFI), normed fix index (NFI), relative fit index (RFI), incremental fix index (IFI), Tucker–Lewis index (TLI), comparative fix index (CFI), root mean square error of approximation (RMSEA), root mean square residual (RMR), parsimonious goodness-fit-index (PGFI), and parsimonious normed fit index (PNFI). In conclusion, the improved NDBCSS-R can provide health professionals with an early understanding of the stress levels of women with breast cancer so that they can provide immediate medical intervention to prevent vicious cycles in a timely manner.

scholarly journals Recommendation and Acceptance of Counselling for Familial Cancer Risk in Newly Diagnosed Breast Cancer Cases

Breast Care ◽  
2021 ◽  
pp. 1-6
Author(s):  
Karin Kast ◽  
Julia Häfner ◽  
Evelin Schröck ◽  
Arne Jahn ◽  
Carmen Werner ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Risk ◽  
Genetic Counselling ◽  
Primary Breast Cancer ◽  
Ductal Carcinoma ◽  
Familial Cancer ◽  
University Hospital ◽  
Tumor Board ◽  
Newly Diagnosed ◽  
Familial Cancer Risk

<b><i>Background:</i></b> In clinical routine, not every patient who is offered genetic counselling and diagnostics in order to investigate a familial cancer risk predisposition opts for it. Little is known about acceptance of counselling and testing in newly diagnosed breast cancer cases in Germany. <b><i>Methods:</i></b> All primary breast cancer cases and patients with DCIS (ductal carcinoma in situ) treated at the University Hospital of Dresden between 2016 and 2019 were included. The number of tumor board recommendations for genetic counselling on the basis of the GC-HBOC risk criteria was recorded. Acceptance was analyzed by number of cases with counselling in the GC-HBOC-Center Dresden. <b><i>Results:</i></b> Of 996 primary breast cancer and DCIS cases, 262 (26.3%) were eligible for genetic counselling. Recommendation for genetic counselling was accepted by 64.1% (168/262). Of these 90.5% (152/168) opted for molecular genetic analysis. The acceptance rate for counselling increased between 2016 and 2019 from 58.3 to 72.6%. Altogether, 20.4% (31/152) patients were found to carry a pathogenic variant in the breast cancer genes <i>BRCA1</i> or <i>BRCA2</i>. <b><i>Conclusion:</i></b> Acceptance of recommendation is increasing as clinical consequences augment. Optimization in providing information about hereditary cancer risk and in accessibility of counselling and testing is required to further improve acceptance of recommendation.

scholarly journals Prospective comparison of the diagnostic accuracy of 18F-FDG PET/MRI, MRI, CT, and bone scintigraphy for the detection of bone metastases in the initial staging of primary breast cancer patients

2021 ◽  
Author(s):  
Nils Martin Bruckmann ◽  
Julian Kirchner ◽  
Lale Umutlu ◽  
Wolfgang Peter Fendler ◽  
Robert Seifert ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Bone Metastases ◽  
Cancer Patients ◽  
Bone Scintigraphy ◽  
Fdg Pet ◽  
Primary Breast Cancer ◽  
Whole Body ◽  
Newly Diagnosed ◽  
Breast Cancer Patients ◽  
Initial Staging

Abstract Objectives To compare the diagnostic performance of [18F]FDG PET/MRI, MRI, CT, and bone scintigraphy for the detection of bone metastases in the initial staging of primary breast cancer patients. Material and methods A cohort of 154 therapy-naive patients with newly diagnosed, histopathologically proven breast cancer was enrolled in this study prospectively. All patients underwent a whole-body [18F]FDG PET/MRI, computed tomography (CT) scan, and a bone scintigraphy prior to therapy. All datasets were evaluated regarding the presence of bone metastases. McNemar χ2 test was performed to compare sensitivity and specificity between the modalities. Results Forty-one bone metastases were present in 7/154 patients (4.5%). Both [18F]FDG PET/MRI and MRI alone were able to detect all of the patients with histopathologically proven bone metastases (sensitivity 100%; specificity 100%) and did not miss any of the 41 malignant lesions (sensitivity 100%). CT detected 5/7 patients (sensitivity 71.4%; specificity 98.6%) and 23/41 lesions (sensitivity 56.1%). Bone scintigraphy detected only 2/7 patients (sensitivity 28.6%) and 15/41 lesions (sensitivity 36.6%). Furthermore, CT and scintigraphy led to false-positive findings of bone metastases in 2 patients and in 1 patient, respectively. The sensitivity of PET/MRI and MRI alone was significantly better compared with CT (p < 0.01, difference 43.9%) and bone scintigraphy (p < 0.01, difference 63.4%). Conclusion [18F]FDG PET/MRI and MRI are significantly better than CT or bone scintigraphy for the detection of bone metastases in patients with newly diagnosed breast cancer. Both CT and bone scintigraphy show a substantially limited sensitivity in detection of bone metastases. Key Points • [18F]FDG PET/MRI and MRI alone are significantly superior to CT and bone scintigraphy for the detection of bone metastases in patients with newly diagnosed breast cancer. • Radiation-free whole-body MRI might serve as modality of choice in detection of bone metastases in breast cancer patients.

scholarly journals Biomarker Modulation following Short-Term Vorinostat in Women with Newly Diagnosed Primary Breast Cancer

2013 ◽  
Vol 19 (14) ◽  
pp. 4008-4016 ◽  
Author(s):  
Vered Stearns ◽  
Lisa K. Jacobs ◽  
MaryJo Fackler ◽  
Theodore N. Tsangaris ◽  
Michelle A. Rudek ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Primary Breast Cancer ◽  
Newly Diagnosed ◽  
Short Term

Clinical utility of breast-specific gamma imaging for evaluating disease extent in the newly diagnosed breast cancer patient

2009 ◽  
Vol 197 (2) ◽  
pp. 159-163 ◽  
Author(s):  
Minhao Zhou ◽  
Nathalie Johnson ◽  
Sam Gruner ◽  
G.W. Ecklund ◽  
Paul Meunier ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patient ◽  
Breast Cancer Patient ◽  
Clinical Utility ◽  
Newly Diagnosed ◽  
Disease Extent ◽  
Gamma Imaging
Sign in / Sign up

Export Citation Format

Share Document